DEAR Study Offers ‘Hope’ to Patients With Non-Metastatic CRPC
June 23rd 2023Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.